


531 Rec'd PCT/PT 29 JAN 2002

Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		ATTY DOCKET NO. 02021	APPLICATION NO. <u>10/3015</u> not assigned			
		APPLICANT Bernard KLEIN ET AL.				
		FILING DATE	GROUP <u>1644</u>			
U. S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
						YES
<u>BSK</u>	9 8 5 3 0 4 8	11/26/98	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)						
<u>BSK</u>	Tarte et al. (1997). Generation of Virtually Pure and Potentially Proliferating Dendritic Cells From Non-CD34 Apheresis Cells From Patients with Multiple Myeloma. Blood, 90(9), 3482-3495.					
	Tarte et al. (1998). Clinical-Grade Functional Dendritic Cells From Patients with Multiple Myeloma Are Not Infected with Kaposi's Sarcoma-Associated Herpersvirus. Blood, 91(6), pp. 1852-1857.					
	Albert et al. (1998). Immature Dendritic Cells Phagocytose Apoptotic Cells Via alphavbeta5 and CD36, and Cross-Present Antigens to Cytotoxic T Lymphocytes. J. Exp. Med., 188(7), 1359-1368.					
	Sallusto et al. (1998). Rapid and Coordinated Switch in Chemokine Receptor Expression During Dendritic Cell Maturation. Eur. J. Immunol., 28, 2760-2769.					
<u>BSK</u>	Kalinski et al. (1998). Prostaglandin E2 Induces the Final Maturation of IL-12-Deficient CD11a ⁺ and CD83 ⁺ Dendritic Cells: The Levels of IL-12 are Determined During the Final Dendritic Cell Maturation and are Resistant to Further Modulation. J. Immunol., 161(6), 2804-2809.					
EXAMINER	<u>BSK</u> 4/8/05		DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						



RECEIVED

JUN 21 2002

TECH CENTER 1600/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.